LITERATURE REVIEW OF PATIENT PERSPECTIVES ON THE MANAGEMENT AND TREATMENT OF PSORIATIC ARTHRITIS

Annelies Boonen1, Neil Betteridge2, Andreas Pinter3, Julie Hill4, Savita Anand5, Colleen McHorney6, Catherine Reed7, Maastricht University, Netherlands; 2Neil Betteridge Associates, London, United Kingdom; 3University Hospital Frankfurt, Frankfurt, Germany; 4Eli Lilly, Windlesham, United Kingdom; 5Evidera, London, United Kingdom; 6Evidera, Bethesda, United States of America

Background: A patient-centred approach to the management and drug treatment of psoriatic arthritis (PsA) has been advocated by a multidisciplinary group of experts to improve skin and joint symptoms and health-related quality of life (HRQoL).

Objectives: To examine perspectives of patients with PsA on: (1) disease management and treatment goals, (2) disease management and treatment satisfaction, and (3) treatment adherence, including reasons for discontinuation. Areas of interest were those related to medication, symptom resolution, everyday living and overall HRQoL.

Methods: A targeted literature review was conducted to identify peer-reviewed literature on patient experience with PsA management and drug treatment. English-language articles published between 1 January 2010–4 October 2018 reporting qualitative or quantitative evidence from cross-sectional or longitudinal observational studies were identified from searches conducted using MEDLINE (via PubMed) and Embase. Selection criteria included adult patients with PsA (self-reported or clinician-diagnosed); drug-treatment studies could consider only regulatory-approved treatments for PsA and other studies had to provide evidence of patient perspectives on disease management and treatment goals, experiences and/or satisfaction. Studies involving paediatric/adolescent populations were excluded, as were results for PsA were not distinguishable from other diseases.

Results: The literature search identified 266 titles, of which 48 duplicates were removed. The remaining 218 abstracts were screened: 58 full-text articles were assessed for eligibility and 16 articles were selected for full-text review. Of these 16 articles, 9 were primarily related to patient perspective on disease management, 6 to patient satisfaction and 1 to treatment adherence; some articles covered more than one of these objectives. None of the articles studied whether explicit consideration of treatment goals from the patient perspective would influence management.

Conclusion: This literature review identified a lack of research on patient perspectives of PsA management and treatment goals. It also highlighted the lack of patient involvement in determining management and setting personal goals, which may ultimately affect satisfaction. There remains a lack of clarity on PsA symptoms and other disease- or patient-related parameters that impact patient satisfaction/dissatisfaction and patient-centred reasons for treatment discontinuation. The findings of this review will be used to develop a PsA patient survey to further explore patient perspectives to improve care in PsA.

REFERENCES:

Disclosure of Interests: Annelies Boonen: None declared, Neil Betteridge Consultant for: Amgen, Eli Lilly, Grunenthal, GSK, Heart Valve Voice, Janssen, Roche, Sanofi Genzyme and Sanofi Regeneron, Speakers bureau: Amgen, Eli Lilly, Grunenthal, GSK, Heart Valve Voice, Janssen, Roche, Sanofi Genzyme and Sanofi Regeneron, Andreas Pinter Consultant for: AbbVie, Almirall Herbal, Amgen, Biogen Idec, Boehringer Ingelheim, Celgene, GSK, Eli Lilly and Company, Galderma, Hexal, Janssen, LEO Pharma, Medac, Merck Serono, Mitsubishi, MSD, Novartis, Pfizer, Tigracet Pharma, Regeneron, Roche, Sandoz Biopharmaceuticals, Schering-Plough and UCB Pharma, Julie Hill Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company, Savita Anand Consultant for: Contracted by Eli Lilly and Company to conduct the literature review., Colleen McHorney Consultant for: Contracted by Eli Lilly and Company to conduct the literature review., Catherine Reed Shareholder of: Eli Lilly and Company, Employee of: Eli Lilly and Company

IXEKIZUMAB MAKES REMISSION AND LOW DISEASE ACTIVITY POSSIBLE IN PATIENTS WITH PSORIATIC ARTHRITIS: TWO-YEAR RESULTS IN TNF INADEQUATE RESPONDERS OR BIOLOGIC-NAIVE PATIENTS

Laura C. Coates1, Alexis Ogide2, Prashanth Sunkureddi3, Lisa Kerr4, Matthew Hulford4, Philip Hellwell4, 1University of Oxford, Oxford, United Kingdom; 2Penn Medicine, Philadelphia, United States of America; 3Clear Lake Rheumatology, League City, United States of America; 4Eli Lilly and Company, Indianapolis, United States of America; 5Univ of Leeds, School of Medicine, Leeds, United Kingdom

Background: Psoriatic arthritis (PsA) is a heterogeneous inflammatory disease that can involve peripheral and axial joints, skin, and entheses. A number of validated composite indices have been developed, not only to measure overall disease activity for PsA, but also to provide thresholds for treat-to-target goals. These include MDA ( Minimal Disease Activity), DAPSA (Disease Activity in PsA), and PASDAS (PsA Disease Activity Score). We have previously demonstrated that higher proportions of PsA patients treated with ixekizumab (IXE), a monoclonal antibody that selectively targets interleukin-17A, achieved therapeutic thresholds defined by MDA, DAPSA, and PASDAS versus placebo (PBO) up to Week 24.

Objectives: To explore the extent to which IXE can help biologic-naive and tumor necrosis factor inhibitor (TNFi) inadequate responder patients achieve treat-to-target goals, as defined by composite indices incorporating multiple disease domains, through 108 weeks of treatment.

Methods: Data were analyzed from all patients initially randomized to 80 mg IXE every 4 weeks after a 160-mg starting dose in 2 double-blind, PBO-controlled phase III trials investigating the efficacy and safety of IXE. For SPIRIT-P1 (NCT01695239), patients (N=107) were bDMARD naïve. For SPIRIT-P2 (NCT02349295), patients (N=112) had an inadequate response or were intolerant to TNFiS. The following composite measures and definitions were used: MDA and Very Low Disease Activity (VLDA) (see Figure); DAPSA Low Disease Activity (LDA) (≤14 and ≤4) and remission (≤4); PASDAS LDA/VLDA (≤3≤2.5 and ≤1.9); and GRACE (GRAppa Composite score) LDA (≤2.3). Modified nonresponder imputation (mNRI; missing data treated as nonresponse for patients discontinued due to lack of efficacy or adverse events; multiple imputation for all other missing data) was used for all analyses.

Results: Therapeutic threshold results at Week 108 are summarized in the Figure. Whether measured using MDA, DAPSA, PASDAS, or GRACE, the proportions of IXE-treated patients achieving designated therapeutic thresholds were sustained through 2 years of treatment. Efficacy was similar between SPIRIT-P1 and SPIRIT-P2.

REFERENCES: